Australia Health

Orthocell (ASX:OCC) has reached a key milestone in its US expansion, achieving 100 unit sales of its flagship nerve repair product, Remplir.

Lumos Diagnostics (ASX:LDX) entered into a new distribution agreement with the Interlux Group to commercialise its FebriDx test across the Baltic region.

TrivarX (ASX:TRI) has reported positive results from its clinical trial evaluating its single-lead ECG algorithm for screening current major depressive episodes in veterans.

Healthscope has confirmed full compliance with its lease obligations, having paid the December rent in full.

Anatara Lifesciences (ASX:ANR), a developer of evidence-based health products, has provided an update on its Anti-Obesity Project.

Neurotech International (ASX: NTI) received binding commitments from investors for approximately $4 million.

Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute.

Proteomics International Laboratories (ASX:PIQ) has been granted a US patent for its proprietary blood test, PromarkerEso.

Wellnex Life (ASX:WNX) provided shareholders with an update on its ongoing turnaround strategy.

Mayne Pharma Group (ASX:MYX) has inaugurated its newly expanded manufacturing facility in Salisbury, South Australia.

Recce Pharmaceuticals (ASX:RCE), a developer of a new class of synthetic anti-infectives, has received an Advanced Overseas Finding from the Australian Department of Industry, Science and Resources

Artrya (ASX:AYA), a medical technology company commercialising its Salix AI-powered cloud platform for near real-time, point-of-care assessment and management of coronary artery disease, has announced that Tanner Health has commenced commercial use of the Salix Coronary Plaque module, generating the first fee-per-scan revenues for the company.